The development process for SPAG11A inhibitors would include several stages of screening and optimization. Initially, high-throughput screening of chemical libraries might be used to identify molecules that can bind to SPAG11A. These compounds would then be tested in a series of in vitro assays to evaluate their capacity to inhibit the protein's function. The assays would be designed to measure specific activities associated with SPAG11A, such as binding affinity to its natural substrates or partners, or any enzymatic activities it may possess. Once potential inhibitors are identified, they would undergo a process of hit-to-lead optimization where their chemical structures are modified to improve their effectiveness at inhibiting SPAG11A, as well as to enhance their selectivity, ensuring that they do not significantly affect the function of other proteins.
This optimization process would involve a cycle of synthesis, testing, and analysis known as the structure-activity relationship (SAR) cycle. SAR helps to understand how changes to the chemical structure influence the biological activity of the compounds. Chemists would make targeted modifications to the inhibitor molecules, such as adding or removing functional groups, to improve binding efficiency and specificity. Computational chemistry would play a significant role in this stage, with molecular modeling and docking studies providing insights into the interaction between SPAG11A and the inhibitor compounds at the molecular level. These techniques can predict how adjustments to the inhibitor's structure might impact its ability to fit into the protein's active site or interfere with its function.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Actinomycin D | 50-76-0 | sc-200906 sc-200906A sc-200906B sc-200906C sc-200906D | 5 mg 25 mg 100 mg 1 g 10 g | $74.00 $243.00 $731.00 $2572.00 $21848.00 | 53 | |
Binds to DNA and inhibits RNA polymerase, which could decrease transcription, potentially affecting SPAG11A expression. | ||||||
α-Amanitin | 23109-05-9 | sc-202440 sc-202440A | 1 mg 5 mg | $269.00 $1050.00 | 26 | |
Inhibits RNA polymerase II, leading to reduced mRNA synthesis, which could lower the levels of SPAG11A mRNA. | ||||||
Cycloheximide | 66-81-9 | sc-3508B sc-3508 sc-3508A | 100 mg 1 g 5 g | $41.00 $84.00 $275.00 | 127 | |
Inhibits eukaryotic protein synthesis by interfering with ribosome function, which could reduce SPAG11A protein levels. | ||||||
Puromycin dihydrochloride | 58-58-2 | sc-108071 sc-108071B sc-108071C sc-108071A | 25 mg 250 mg 1 g 50 mg | $42.00 $214.00 $832.00 $66.00 | 394 | |
Causes premature termination of protein synthesis, potentially reducing the levels of many proteins, including SPAG11A. | ||||||
Emetine | 483-18-1 | sc-470668 sc-470668A sc-470668B sc-470668C | 1 mg 10 mg 50 mg 100 mg | $440.00 $900.00 $1400.00 $2502.00 | ||
Inhibits protein synthesis by blocking ribosomal translocation, possibly affecting SPAG11A production. | ||||||
Triptolide | 38748-32-2 | sc-200122 sc-200122A | 1 mg 5 mg | $90.00 $204.00 | 13 | |
Inhibits a wide range of gene transcription activities by modulating RNA polymerase II, potentially lowering SPAG11A expression. | ||||||
Anisomycin | 22862-76-6 | sc-3524 sc-3524A | 5 mg 50 mg | $99.00 $259.00 | 36 | |
Inhibits peptide bond formation at the ribosome, which could decrease protein synthesis, including that of SPAG11A. | ||||||
Chloramphenicol | 56-75-7 | sc-3594 | 25 g | $90.00 | 10 | |
Targets bacterial ribosomes but can also affect mitochondrial protein synthesis, potentially impacting SPAG11A. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Inhibits mTOR signaling, which has broad effects on cell growth and protein synthesis, potentially affecting SPAG11A levels. | ||||||
Homoharringtonine | 26833-87-4 | sc-202652 sc-202652A sc-202652B | 1 mg 5 mg 10 mg | $52.00 $125.00 $182.00 | 11 | |
Blocks peptide chain elongation during translation, which could lead to reduced synthesis of proteins including SPAG11A. | ||||||